Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000938707
Ethics application status
Approved
Date submitted
21/08/2013
Date registered
26/08/2013
Date last updated
12/11/2018
Date data sharing statement initially provided
12/11/2018
Date results provided
12/11/2018
Type of registration
Prospectively registered
Titles & IDs
Public title
Predicting response to biologics in rheumatoid arthritis
Query!
Scientific title
Predicting response to biologics in rheumatoid arthritis
Query!
Secondary ID [1]
283048
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid arthritis
289885
0
Query!
Condition category
Condition code
Inflammatory and Immune System
290250
290250
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
False
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
This is an observational study. Patients receiving bioloigic therapy for treatment of rheumatoid arthritis will be recruited. Patients will be seen prior to treatment and at 4-6 months after commencing treatment. Disease activity will be assessed using standard measures including swollen joint count, tender joint count, C reactive protein and the composite disease acitivty score 28.
Query!
Intervention code [1]
287766
0
Not applicable
Query!
Comparator / control treatment
Nil
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
290267
0
Response to biologic as determined by disease activity score
Query!
Assessment method [1]
290267
0
Query!
Timepoint [1]
290267
0
4 months
Query!
Secondary outcome [1]
304224
0
Change in inflammatory cytokines measured in the serum
Query!
Assessment method [1]
304224
0
Query!
Timepoint [1]
304224
0
4 months
Query!
Secondary outcome [2]
304283
0
Change in gene expression in peripheral blood cells measured by quantitative polymerase chain reaction
Query!
Assessment method [2]
304283
0
Query!
Timepoint [2]
304283
0
4 months
Query!
Eligibility
Key inclusion criteria
Patients with rheumatoid arthritis as defined by American College of Rheumatology Criteria whom the treating clinician has started biological therapy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Unwilling to provide informed consent
Query!
Study design
Purpose
Natural history
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
2/09/2013
Query!
Actual
12/11/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
1/09/2016
Query!
Date of last data collection
Anticipated
Query!
Actual
5/12/2016
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
100
Query!
Recruitment outside Australia
Country [1]
5322
0
New Zealand
Query!
State/province [1]
5322
0
Christchurch
Query!
Country [2]
5323
0
New Zealand
Query!
State/province [2]
5323
0
Dunedin
Query!
Funding & Sponsors
Funding source category [1]
287812
0
Government body
Query!
Name [1]
287812
0
Health Research Council of New Zealand
Query!
Address [1]
287812
0
PO Box 5541,
Wellesley Street,
Auckland 1141
Query!
Country [1]
287812
0
New Zealand
Query!
Primary sponsor type
University
Query!
Name
University of Otago, Christchurch
Query!
Address
P.O.Box 4345
Christchurch 8014
Query!
Country
New Zealand
Query!
Secondary sponsor category [1]
286541
0
None
Query!
Name [1]
286541
0
Query!
Address [1]
286541
0
Query!
Country [1]
286541
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289762
0
University of Otago Ethics Committee
Query!
Ethics committee address [1]
289762
0
P.O.Box 56 Dunedin 9054
Query!
Ethics committee country [1]
289762
0
New Zealand
Query!
Date submitted for ethics approval [1]
289762
0
Query!
Approval date [1]
289762
0
02/08/2013
Query!
Ethics approval number [1]
289762
0
13/040
Query!
Summary
Brief summary
The introduction of “biological” disease modifying anti-rheumatic drugs (bDMARDs) has been a major advance in the treatment of rheumatoid arthritis (RA). When conventional therapy fails, bDMARD therapy can be life changing. bDMARDs specifically target key components in the pathways of inflammation causing RA, such as the pro-inflammatory cytokine tumour necrosis factor-a (TNF). Consequently, knowledge of the inflammatory pathways active in individual patients is required for efficient targeting of bDMARDs. We have established a classification of joint synovial tissues, based on the expression of interleukin (IL) 17-A and CD21L genes, reflecting different inflammatory states. Our objective is to determine if we can predict response to anti-TNF therapy based on this system and concentrations of IL-17-related cytokines. The ability to predict response to treatment will improve outcomes for patients with RA and provide cost savings by ensuring that those patients most likely to respond receive these highly effective but expensive drugs.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
42286
0
Prof Lisa Stamp
Query!
Address
42286
0
Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014
Query!
Country
42286
0
New Zealand
Query!
Phone
42286
0
+6433640953
Query!
Fax
42286
0
Query!
Email
42286
0
[email protected]
Query!
Contact person for public queries
Name
42287
0
Lisa Stamp
Query!
Address
42287
0
Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014
Query!
Country
42287
0
New Zealand
Query!
Phone
42287
0
+6433640953
Query!
Fax
42287
0
Query!
Email
42287
0
[email protected]
Query!
Contact person for scientific queries
Name
42288
0
Lisa Stamp
Query!
Address
42288
0
Department of Medicine
University of Otago, Christchurch
P.O.Box 4345
Christchurch 8014
Query!
Country
42288
0
New Zealand
Query!
Phone
42288
0
+6433640953
Query!
Fax
42288
0
Query!
Email
42288
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF